Faxen-Irving 2013 | -0.8 | 2.78 | 89 | -0.8 | 2.68 | 85 | 62.7% | 0.00 [-0.81,0.81] |
Quinn 2010 | -3.7 | 5.82 | 238 | -4.04 | 5.29 | 164 | 34.3% | 0.34 [-0.76,1.44] |
Shinto 2014 | -4.3 | 4.31 | 11 | -4.6 | 4.64 | 11 | 2.9% | 0.30 [-3.44,4.04] |
Total (95% CI) | | | 338 | | | 260 | 100% | 0.13 [-0.52,0.77] |
Heterogeneity: Tau2=0.00; Chi2=0.25, df=2 (p=0.88); I2=0% |
Test for overall effect: Z=0.38 (p=0.70) |
Study or Sub group | Polymeric formula | Control | Weight | Mean Difference |
Mean | SD | Total | Mean | SD | Total | IV, Random, 95% CI |
Kamphuis 2011 | 1.2 | 10.6 | 101 | 0.7 | 11.15 | 99 | 23.0% | 0.50 [-2.52,3.52] |
Remington 2015 | 1.4 | 109.7 | 48 | -0.9 | 111.4 | 34 | 0.1% | 2.30 [-46.33,50.93] |
Shah 2013 | -3.74 | 9.76 | 228 | -3.66 | 8.03 | 223 | 76.9% | -0.08 [-1.73,1.57] |
Total (95% CI) | | | 377 | | | 356 | 100% | 0.06 [-1.39,1.50] |
Heterogeneity: Tau2=0.00; Chi2=0.12, df=2 (p=0.94); I2=0% |
Test for overall effect: Z=0.08 (p=0.94) |
Study or Sub group | DHA | Control | Weight | Mean Difference |
Mean | SD | Total | Mean | SD | Total | IV, Random, 95% CI |
Astarita 2010 | 102.99 | 40.66 | 36 | 123.61 | 24.07 | 17 | 0.2% | -21.32 [-38.85,-3.79] |
Fontech 2014 | 15.3 | 2.2 | 29 | 16.8 | 3.3 | 69 | 17.1% | -1.50 [-2.62,-0.38] |
Fraser 2010 | 14.51 | 2.42 | 86 | 14.98 | 1.53 | 55 | 22.1% | -0.47 [-1.12,0.18] |
Igarashi 2011 | 6.626 | 1.038 | 10 | 7.244 | 1.903 | 9 | 0.0% | -618.00 [-2017.86,781.86] |
Martin 2010 | 4.91 | 1.74 | 10 | 6.87 | 1.07 | 10 | 15.5% | -1.96 [-3.23,-0.69] |
Quinn 2010 | 3.18 | 1.21 | 238 | 3.13 | 0.96 | 164 | 25.6% | 0.05 [-0.16,0.26] |
Schektens 2012 | 6.5 | 0 | 114 | 3 | 0 | 119 | | Not estimable |
Shah 2013 | 6.3 | 0 | 239 | 2.5 | 0 | 232 | | Not estimable |
Shinto 2014 | 5.1 | 1.3 | 13 | 4.4 | 1 | 13 | 19.5% | 0.70 [-0.19,1.59] |
Total (95% CI) | | | 775 | | | 688 | 100% | -0.56 [-1.34,0.23] |
Heterogeneity: Tau2=0.61; Chi2=26.77, df=6 (p=0.0002); I2=78% |
Test for overall effect: Z=1.39 (p=0.16) |